Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: The significance of dietary cholesterol

References

• Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31
   PubMed Web of Science ®Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9
   PubMed Web of Science ®Google Scholar
• Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954–61
   PubMed Web of Science ®Google Scholar
• Nonomura A, Enomoto Y, Takeda M, Tamura T, Kasai T, Yoshikawa T, et al. Clinical and pathological features of non-alcoholic steatohepatitis. Hepatol Res 2005; 33: 116–21
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909–15
   PubMed Web of Science ®Google Scholar
• Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 2004; 49: 1578–83
   PubMed Web of Science ®Google Scholar
• Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, et al. Influence of insulin resistance and adipokines in the grade of steatosis of non-alcoholic fatty liver disease. Dig Dis Sci 2008; 53: 1088–92
   PubMed Web of Science ®Google Scholar
• Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Insulin resistance and body fat distribution. Diabetes Care 1996; 19: 287–91
   PubMed Web of Science ®Google Scholar
• Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACPR30. Nat Med 2002; 8: 731–7
   PubMed Web of Science ®Google Scholar
• Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 2006; 41: 462–9
   PubMed Web of Science ®Google Scholar
• Tsochatzis E, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 27: 80–9
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169–75
   PubMedGoogle Scholar
• Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin: a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264–80
   PubMed Web of Science ®Google Scholar
• Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferators-activated receptor α gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the α2 form of AMP-activated protein kinase. Mol Cell Biol 2007; 27: 4317–27
   PubMed Web of Science ®Google Scholar
• Bjørbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999; 274: 30059–65
   PubMed Web of Science ®Google Scholar
• Kimura A, Kinjyo I, Matsumura Y, Mori H, Mashima R, Harada M, et al. SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling. J Biol Chem 2004; 279: 6905–10
   PubMed Web of Science ®Google Scholar
• Ghafoorunissa, Ibrahim A, Rajkumar L, Acharya V. Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats. J Nutr 2005; 135: 2634–8
   PubMed Web of Science ®Google Scholar
• Levy JR, Clore JN, Stevens W. Dietary n-3 poly unsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004; 39: 608–16
   PubMed Web of Science ®Google Scholar
• Murase T, Aoki M, Tokimitsu I. Supplementation with α-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of oxidation in Zucker fatty rats. Biochim Biophys Acta 2005; 1733: 224–31
   PubMed Web of Science ®Google Scholar
• Schmocker C, Weylandt KH, Kahlke L, Wang J, Lobeck H, Tiegs G, et al. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology 2007; 45: 864–9
   PubMed Web of Science ®Google Scholar
• Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529–39
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats. Role of peroxisome proliferators-activated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169: 846–60
   PubMed Web of Science ®Google Scholar
• Teran-Garcia M, Adamson AW, Yu G, Rufo C, Suchankova G, Dreesen TD, Tekle M, et al. Polyunsaturated fatty acids suppression by fatty acid synthase (FASN): evidence for dietary modulation of NF-Y binding to the FASN promoter by SREBP-1c. Biochem J 2007; 402: 591–600
   PubMed Web of Science ®Google Scholar
• Kohjima M ,Enjoji M ,Higuchi N ,Kato M ,Kotoh K ,Nakashima M , , et al.The effects of unsaturated fatty acids on lipid metabolism in HepG2 cells. In Vitro Cell Dev Biol Animal. In press
   Web of Science ®Google Scholar
• Jeong WI, Jeong DH, Do SH, Kim YK, Park HY, Kwon OD, et al. Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 2005; 67: 235–42
   PubMed Web of Science ®Google Scholar
• Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006; 41: 971–80
   PubMed Web of Science ®Google Scholar
• Nakamuta M, Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. The significance of differences in fatty acid metabolism between obese and non-obese patients with nonalcoholic fatty liver disease. Int J Mol Med 2008; 22: 663–7
   PubMed Web of Science ®Google Scholar
• Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607–14
   PubMed Web of Science ®Google Scholar
• Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007; 20: 351–8
   PubMed Web of Science ®Google Scholar
• Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008; 21: 507–11
   PubMed Web of Science ®Google Scholar